Cadila Healthcare is currently trading at Rs. 478.50, up by 0.35 points or 0.07% from its previous closing of Rs. 478.15 on the BSE.
The scrip opened at Rs. 480.20 and has touched a high and low of Rs. 482.55 and Rs. 475.30 respectively. So far 201467 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 509.35 on 15-Jan-2021 and a 52 week low of Rs. 212.70 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 482.60 and Rs. 442.50 respectively. The current market cap of the company is Rs. 48934.90 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.97% respectively.
Zydus Cadila has completed Phase -I trials of ZY19489-A single dose cure for Malaria in collaboration with Malaria Venture (MMV). In the first in humans study conducted in Australia, escalating doses of 25 to 1500 mg were administered to healthy human volunteers. Emerging pharmacokinetic (PK) and safety data were evaluated by a safety data review committee.ZY19489 has the potential to be a single-dose cure for P. falciparum and P. vivax malaria due to its novel mechanism of action, rapid parasites killing activity across all intraerythrocytic malaria stages, low resistance potential and long half-life.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1661.00 |
| Dr. Reddys Lab | 1220.35 |
| Cipla | 1234.05 |
| Zydus Lifesciences | 930.95 |
| Lupin | 2307.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: